{"entity":{"id":"nct06095089","kind":"trial","name":"A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer","aka":[],"tldr":"A phase 1 trial of HLD-0915 (JNJ-101556143) run by Janssen Research & Development, LLC, now recruiting.","summary":"A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer is a phase 1 interventional study registered as NCT06095089 by Janssen Research & Development, LLC, with 355 participants planned, started 2023-11-01. Conditions recorded: Prostatic Neoplasms. Interventions recorded: JNJ-78278343, JNJ-87189401, Apalutamide, Lutetium Lu-177 Vipivotide Tetraxetan and JNJ-101556143.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT06095089","url":"https://clinicaltrials.gov/study/NCT06095089"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["hld-0915"],"companies":["halda-therapeutics","johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06095089","phase":"1","setting":"A Phase 1 Study of JNJ-87189401 (PSMA-CD28 Bispecific Antibody) Combined With JNJ-78278343 (KLK2-CD3 Bispecific Antibody) for Advanced Prostate Cancer","sponsor":"Janssen Research & Development, LLC","enrolled":355,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06095089/","neighbours":{"cancer":[{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"drug":[{"id":"hld-0915","kind":"drug","name":"HLD-0915 (JNJ-101556143)","route":"/drugs/hld-0915/"}],"company":[{"id":"halda-therapeutics","kind":"company","name":"Halda Therapeutics","route":"/companies/halda-therapeutics/"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}